MX2021007335A - Forma amorfa y proceso. - Google Patents

Forma amorfa y proceso.

Info

Publication number
MX2021007335A
MX2021007335A MX2021007335A MX2021007335A MX2021007335A MX 2021007335 A MX2021007335 A MX 2021007335A MX 2021007335 A MX2021007335 A MX 2021007335A MX 2021007335 A MX2021007335 A MX 2021007335A MX 2021007335 A MX2021007335 A MX 2021007335A
Authority
MX
Mexico
Prior art keywords
amorphous form
galactopyranosid
trifluo
rophenyl
bromopyridin
Prior art date
Application number
MX2021007335A
Other languages
English (en)
Inventor
Peter Timmins
Lise Gravelle
Anders Pedersen
Original Assignee
Galecto Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galecto Biotech Ab filed Critical Galecto Biotech Ab
Publication of MX2021007335A publication Critical patent/MX2021007335A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se relaciona con una forma amorfa estabilizada de un compuesto de fórmula I así como composiciones para administración oral que comprenden el compuesto de fórmula I en una cantidad terapéuticamente efectiva.
MX2021007335A 2018-12-19 2019-12-18 Forma amorfa y proceso. MX2021007335A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18213993 2018-12-19
EP19159227 2019-02-25
EP19159222 2019-02-25
PCT/EP2019/085912 WO2020127461A1 (en) 2018-12-19 2019-12-18 Amorphous form of 5-bromopyridin-3-yl 3-deoxy-3-[4-(3,4,5-trifluorophenyl)-1h-1,2,3-triazol-1-yl]-1-thio-alpha-d-galactopyranoside

Publications (1)

Publication Number Publication Date
MX2021007335A true MX2021007335A (es) 2021-07-15

Family

ID=69182475

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007335A MX2021007335A (es) 2018-12-19 2019-12-18 Forma amorfa y proceso.

Country Status (9)

Country Link
US (1) US20220064204A1 (es)
EP (1) EP3898644A1 (es)
JP (1) JP2022516437A (es)
KR (1) KR20210106477A (es)
CN (1) CN113330019A (es)
BR (1) BR112021011657A2 (es)
CA (1) CA3122935A1 (es)
MX (1) MX2021007335A (es)
WO (1) WO2020127461A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113956A1 (en) * 2018-10-15 2020-04-23 Galecto Biotech Ab Galactoside inhibitor of galectins
CN114933619B (zh) * 2022-05-18 2024-03-01 上海科利生物医药有限公司 一类硫代糖苷列净类似物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
NO2802319T3 (es) * 2012-01-12 2018-03-24
CN104918608A (zh) * 2012-11-19 2015-09-16 雷迪博士实验室有限公司 Cetp抑制剂的药物组合物
JP6904906B2 (ja) * 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤

Also Published As

Publication number Publication date
WO2020127461A1 (en) 2020-06-25
US20220064204A1 (en) 2022-03-03
BR112021011657A2 (pt) 2021-09-08
KR20210106477A (ko) 2021-08-30
JP2022516437A (ja) 2022-02-28
EP3898644A1 (en) 2021-10-27
CA3122935A1 (en) 2020-06-25
CN113330019A (zh) 2021-08-31

Similar Documents

Publication Publication Date Title
MX2023003067A (es) Oxadiazoles fungicidas.
MX2021005295A (es) Tolilos sustituidos como fungidas.
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
HN2011000699A (es) El compuesto (s)-1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del acido pirrolidin-1,2-dicarboxilico en forma libre o de sal y composiciones y composicion farmaceutica que lo contiene.
NZ627464A (en) Fungicidal pyrazole mixtures
MX2014001671A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-aluiniloxi-etil}-1h[1,2,4]triazol sustituidos.
MX2017010735A (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
PH12013500848B1 (en) Trpv1 antagonists and uses thereof
MX2013014348A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-feni]-2 -alcoxi-2-ciclil-etil}-1h-[1,2,4]triazol sustituidos.
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
MY158777A (en) Oral compositions containing polyguanidinium compounds and methods of manufacture and use thereof
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
MX2013004162A (es) Composiciones farmaceuticas que contienen un inhibidor de dgat1.
NZ710574A (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
MX2021002460A (es) Pirazoles fungicidas sustituidos con nitroanilino.
MX2011008959A (es) Compuestos carbonatos de anti-biopelicula para su uso en composiciones para el cuidado oral.
WO2014102592A3 (en) Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
MX2021007335A (es) Forma amorfa y proceso.
SG10201907291QA (en) Monomethylfumarate prodrug compositions
MX2020005646A (es) Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2 -(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-aci do ciclo-propilpropanoico y su forma cristalina para uso como principio activo farmaceutico.
MX2013003390A (es) Imidazoles fungicidas.
MX2020001199A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.